<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652090</url>
  </required_header>
  <id_info>
    <org_study_id>2010-05-03 A3</org_study_id>
    <nct_id>NCT03652090</nct_id>
  </id_info>
  <brief_title>Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis</brief_title>
  <acronym>Epiithelix</acronym>
  <official_title>Evaluation of the Primary Human Nasal Epithelial Cell Culture Model in the Context of Personalized Therapy in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ABCF2</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      characterization of CFTR function and expression in nasal primary cells collected from
      patients with cystic fibrosis in comparison to their parents, healthy heterozygotes and
      healthy controls
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 groups of subjects are enrolled CF subjects according to their genotypes (aiming to enroll
      patients carrying 2 CF causing mutations with no CFTR expression/function, and patients
      carrying at least 1 mutation with residual function, such R117H) Parents or siblings of the
      CF subjects, as healthy hétérozygotes healthy controls All these subjects experience nasal
      brushings. From these nasal brushings,nasal cells are expanded, and cultured in air liquid
      interface to obtain polarized epithelium. This epithelium is then studied in Ussing chamber
      experiments to characterize the level of cAMP dependant Chloride transport and Sodium
      reabsorption. Apical expression of CFTR is assessed by immunofluorescence.

      Results will allow to define the variability of CFTR function and expression criteria in
      subjects with the same genotype. Such data are crucial for interpretation of the effect of
      CFTR modulators.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2010</start_date>
  <completion_date type="Actual">March 3, 2016</completion_date>
  <primary_completion_date type="Actual">March 3, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>variation in the short-circuit-current (Isc) after Forskolin (Forskolin)/IBMx and VX-770 (∆IscFsk/IBMx+VX-770)</measure>
    <time_frame>1 day</time_frame>
    <description>The short-circuit-current (Isc) was measured under voltage clamp conditions. Inhibitors and activators were added after stabilization of baseline Isc. The sum of the change after Forskolin (Forskolin)/IBMx and VX-770 (∆IscFsk/IBMx+VX-770) served as an index of CFTR function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of cells displaying apical staining</measure>
    <time_frame>1 day</time_frame>
    <description>CFTR immuno-detection was performed as previously described 31. Apical CFTR staining was assessed semi quantitatively as the percentage of cells displaying apical staining multiplied by the average corrected apical fluorescence 32.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">112</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>cystic fibrosis patients</arm_group_label>
    <description>Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy heterozygotes</arm_group_label>
    <description>healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cell sampling</intervention_name>
    <description>nasal brushing to collect cells</description>
    <arm_group_label>cystic fibrosis patients</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_label>healthy heterozygotes</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      p
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Cystic Fibrosis with 2 mutations in CFTR

          -  healthy heterozygotes with 1 mutation in CFTR

          -  healthy subjects with no familial history of Cystic Fibrosis and no symptoms
             compatibel with Cystic Fibrosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Cystic Fibrosis with 2 mutations in CFTR

          -  healthy heterozygotes with 1 mutation in CFTR

          -  healthy subjects with no familial history of Cystic Fibrosis and no symptoms
             suggesting Cystic Fibrosis

        Exclusion Criteria:

          -  smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut National de la Santé Et de la Recherche Médicale, France</investigator_affiliation>
    <investigator_full_name>Isabelle Sermet-Gaudelus</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

